An interventional study of Manual Acupuncture and Electroacupuncture in Functional Constipation (FC), sponsored by Tongji Hospital. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-14.
Sponsored by Tongji Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 109 studies in Constipation with a site in China — 35 open to participants now, 37 under way, 1 of them phase 3. Constipation · China.
Among the 109 studies in Constipation with a site in China, this one is the 61st largest by planned enrollment of the 93 interventional ones that give a count, is one of 11 that started in 2026, is one of 56 with no phase, reaches primary completion later than 29 of the 36 other live ones, and was the 101st registered.
1,051 studies on the registry are indexed under Constipation; 163 are open to participants now.
Browse Constipation studies →35 of the 109 studies in Constipation with a site in China are open now. Recruiting first, the newest first:
Wecare Probiotics Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Wecare Probiotics Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Wecare Probiotics Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Eli Lilly and Company · Sites in China, United States, Belgium and 5 more countries
Ages 18–75
Third Military Medical University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
109 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 23 · Phase 3 9 · Phase 4 3
First in 2004; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is close to the median of 75 across 889 interventional studies indexed under Constipation.
Median enrollment 100 across the 93 interventional studies, 278 across the 16 observational. Of the 50 that completed or were terminated, 6 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 109 have an industry lead sponsor. The 10 most frequent:
Tongji Hospital is the lead sponsor of 392 studies on the registry; 213 are open to participants now.
Tongji Hospital has 3 studies filed under Constipation — fewer than ten, so there is no comparison to draw.
13 of the studies in Constipation with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07277907Phase 3Third Military Medical UniversityEfficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation | 2027-10-31 |
| NCT07507955Wecare Probiotics Co., Ltd.Probiotics for Constipation Relief in Adults | 2026-11-30 |
| NCT07765004Wecare Probiotics Co., Ltd.Probiotics Improve Constipation | 2026-12-15 |
| NCT07648394China-Japan Friendship HospitalResearch on the Efficacy and Mechanism of Shouhui Tongbian Capsules in Treating Postoperative Constipation of Benign Anal and Rectal Diseases Based on Gut Microbiota Analysis | 2026-12-31 |
| NCT07387952Peking Union Medical College HospitalThe Safety and Efficacy of Fecal Microbiota Transplantation Combined With Nutritional Intervention in the Treatment of Functional Constipation:a Pilot Study | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 109 studies in Constipation with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-center, randomized, parallel-group trial evaluating the dose-response relationship of two experimental interventions: manual acupuncture and electroacupuncture for functional constipation.
A total of 72 participants with functional constipation (Rome IV criteria) will be randomly assigned in a 1:1 ratio to either the manual acupuncture group or the electroacupuncture group. Both groups receive acupuncture at bilateral Tianshu (ST25) and Shangjuxu (ST37) points, 30 minutes per session, three times per week for 12 weeks. The electroacupuncture group additionally receives electrical stimulation (continuous wave, 10 Hz, 0.5-4 mA).
The primary outcome is the responder rate at week 12, defined as the percentage of participants with ≥3 complete spontaneous bowel movements (CSBMs) per week. Secondary outcomes include changes in gut microbiota, brain functional connectivity measured by multimodal MRI and fNIRS, and scales.
The study aims to clarify the dose-response characteristics of different acupuncture modalities and their underlying biological mechanisms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Manual Acupuncture
Device: Electroacupuncture
Acupuncture at bilateral Tianshu (ST25) and Shangjuxu (ST37). Participant lies supine and rests for 5 minutes before treatment. After routine disinfection, the acupuncturist inserts needles vertically to a certain depth, followed by mild lifting, thrusting, and twisting for 10 seconds at each acupoint to induce deqi. Needles are retained for 30 minutes. After removal, needle holes are pressed to prevent bleeding. Treatment frequency: three sessions per week for 12 weeks.
Acupuncture at bilateral Tianshu (ST25) and Shangjuxu (ST37). Participant lies supine and rests for 5 minutes before treatment. After routine disinfection, the acupuncturist inserts needles vertically to a certain depth, followed by mild lifting, thrusting, and twisting for 10 seconds at each acupoint to induce deqi. Then needles are connected to an electroacupuncture device (Hwato SDZ-III, Suzhou Medical Products Factory, China). Two pairs of electrodes are attached: one pair to bilateral Tianshu (ST25), the other to bilateral Shangjuxu (ST37). Electrical stimulation: continuous wave, 10 Hz, current intensity 0.5-4 mA adjusted to patient tolerance. Electroacupuncture duration: 30 minutes. After needle removal, press to prevent bleeding. Treatment frequency: three sessions per week for 12 weeks.
Responder Rate at Week 12
Percentage of participants with ≥3 complete spontaneous bowel movements (CSBMs) per week at week 12
Time frame: Week 12
Responder Rate at Week 16
Percentage of participants with ≥3 complete spontaneous bowel movements (CSBMs) per week at week 16
Time frame: Week 16
Changes in Blood Flow Measured by DCS
Changes in blood flow at acupoints, intestinal body surface projection areas, and abdominal muscle tissue measured by diffuse correlation spectroscopy (DCS), with concurrent monitoring of local pressure and temperature
Time frame: Baseline, after deqi, weeks 2, 4, 6, 8, 10, 12, 16
Changes in Gut Microbiota
Changes in gut microbiota diversity and composition analyzed by 16S rRNA sequencing, and changes in gut metabolites (e.g., short-chain fatty acids) measured by targeted metabolomics
Time frame: Baseline, week 12, week 16, and at the time when CSBMs ≥3 per week is achieved
Changes in Brain Function
Changes in central neural network connectivity, functional activity of core brain regions, and brain glymphatic system function assessed by multimodal MRI
Time frame: Baseline, after deqi, week 12, week 16, and at the time when CSBMs ≥3 per week is achieved
Changes in Cortical Activity Measured by fNIRS
Changes in cortical activity assessed by functional near-infrared spectroscopy (fNIRS)
Time frame: Baseline, after deqi, weeks 2, 4, 6, 8, 10, 12, 16
Acupuncture Expectancy Scale
A 4-item patient-reported questionnaire assessing patients' expectancy of positive outcomes from acupuncture therapy, including improvement of illness, enhanced coping, increased vitality, and symptom alleviation. Each item is scored from 1 (not at all agree) to 5 (completely agree), with total scores ranging from 4 to 20. Higher scores indicate greater expectancy of benefit from acupuncture treatment.
Time frame: Baseline
Patient Assessment of Constipation Quality of Life
A 28-item patient-reported questionnaire assessing constipation-related quality of life, consisting of four domains: physical discomfort, psychosocial discomfort, worries and concerns, and satisfaction. Each item is scored from 0 to 4, with total scores ranging from 0 to 112. Higher scores indicate worse constipation-related quality of life.
Time frame: Baseline, weeks 2, 4, 6, 8, 10, 12, 16
Generalized Anxiety Disorder 7-item Scale
A 7-item patient-reported questionnaire assessing anxiety symptoms over the past two weeks. Each item is scored from 0 (not at all) to 3 (nearly every day), with total scores ranging from 0 to 21. Higher scores indicate more severe anxiety symptoms.
Time frame: Baseline, weeks 2, 4, 6, 8, 10, 12, 16
Patient Health Questionnaire-9
A 9-item patient-reported questionnaire assessing depressive symptoms over the past two weeks, based on the DSM-IV diagnostic criteria for depression. Each item is scored from 0 (not at all) to 3 (nearly every day), with total scores ranging from 0 to 27. Higher scores indicate more severe depressive symptoms.
Time frame: Baseline, weeks 2, 4, 6, 8, 10, 12, 16
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Sep 2027, 16 months after the start.
Of 246 non-industry interventional studies with no phase under Constipation, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's planned 16 months is close to that.
Counting every sponsor, half of 317 studies reached it within 14 months; a quarter within 6 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.